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Background
Phosphodiesterase type-5 is a cGMP-selective PDE
expressed in heart, and growing evidence supports its
importance in modifying cardiac stress response signal-
ling. Recent human studies have reported PDE5A myocyte
expression notably in disease conditions such as hypertro-
phy and dilated heart failure. We have shown that upreg-
ulating PDE5A in isolated myocytes stimulates cellular
hypertrophy. This is now demonstrated in vivo using a
new tetracycline-controllable myocyte-targeted overex-
pression mouse model. Upregulation of PDE5A in myo-
cytes lowers PKG activation, and results in gradual
chamber dilation, hypertrophy, and dysfunction. In
hearts from younger transgenic animals (without basal
abnormalities), PDE5A overexpression worsens the
response to pressure-overload stress. A major target of
PDE5A-inhibitor mediated anti-hypertrophic signalling
appears to be Gaq-receptor activation by both neurohu-
moral ligands and mechanical stimuli. Here we report sev-
eral new mechanisms by which this is achieved.
Results
In one study, mice lacking the regulator of G-protein sig-
nalling 2 (RGS2) show profoundly worse responses to
pressure-overload, with early hypertrophy, dilation, dys-
function, and lethality. Despite elevation of PKG in these
hearts treated with sildenafil as in littermate controls, the
RGS2-null heart does not respond to PDE5A inhibition
(with less hypertrophy, improved function, etc.) whereas
the controls do. PKG-RGS2 interaction is important to
this signalling. In a second series of studies, we identified
a novel PKG regulation of transient receptor potential
canonical channel protein (TRPC6). TRPC6 has been
shown to serve as a ligand and stretch responsive channel
for Ca2+ conductance – that couples to Ca2+-calmodulin/
calcineurin/NFAT activation. Recent evidence in embry-
onic aortic smooth muscle has shown TRPC6 can be PKG
phosphorylated at T11, reducing conductance. We have
found PKG also phosphorylates TRPC6 in myocytes, iden-
tifying two functional sites, and that this is coupled with
changes in conductance modulation by cGMP/PKG and
with antihypertrophic signalling effects of sildenafil
linked to the suppression of NFAT activity induced by Gq-
receptor agonists. Gain or loss of function phosphor-
mutants confirm the functionality of this modulation by
PKG.
Conclusion
As TRPC6 is also thought to play an important role in
hypertension, and gain of function missense mutations
lead to human glomerulosclerosis, the ability of sildenafil
to suppress conductance may have broader implications
beyond cardiac disease.
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